Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugateПодробнее

Trastuzumab Cardiotoxicity in DESTINY-Breast04 TrialПодробнее

Capivasertib in Advanced Breast Cancer | NEJMПодробнее

NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerПодробнее

Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?Подробнее

Trastuzumab Deruxtecan for Breast Cancer | NEJMПодробнее

New breast cancer drug delivers unprecedented levels of survival, stopping tumor growthПодробнее

Reducing Risk in Residual Breast CancerПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Clinical outcomes in women with metastatic HER2-low breast cancer in the real worldПодробнее

Ribociclib in Early Breast Cancer | NEJMПодробнее

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

ENHERTU Therapy: A Powerful New Cancer TreatmentПодробнее

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in ReviewПодробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

NEJM Interview: Dr. H. Gilbert Welch on trends in the incidence of metastatic cancers and their i...Подробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast CancerПодробнее

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvementПодробнее